Evaluating the Cost-Effectiveness of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in the Treatment of Patients with Insulin-Treated Type 2 Diabetes in Australia

RT-CGM was dominant in both insulin-treated subgroups, improving patient outcomes while reducing healthcare costs. These findings highlight the potential value of RT-CGM for broad reimbursement in Australia and the importance of addressing inequities in glycemic management, particularly among Indigenous Australians and younger individuals with T2D.